Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q969S9
UPID:
RRF2M_HUMAN
Alternative names:
Elongation factor G 2, mitochondrial; Elongation factor G2
Alternative UPACC:
Q969S9; A0AR28; Q8N6D8; Q8WYI0; Q9H6Z1
Background:
Ribosome-releasing factor 2, mitochondrial, also known as Elongation factor G2, plays a crucial role in mitochondrial protein biosynthesis. It mediates the disassembly of ribosomes from messenger RNA post-translation, in collaboration with MRRF, ensuring efficient mitochondrial function.
Therapeutic significance:
Linked to Combined oxidative phosphorylation deficiency 39, a disorder stemming from mitochondrial dysfunction, understanding Ribosome-releasing factor 2's role could open doors to potential therapeutic strategies.